Literature summary extracted from

Graham, M.J.; Lemonidis, K.M.; Whipple, C.P.; Subramaniam, A.; Monia, B.P.; Crooke, S.T.; Crooke, R.M.
Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice (2007), J. Lipid Res., 48, 763-767.

Application

EC Number	Application	Comment	Organism
3.4.21.61	medicine	antisense inhibition of PCSK9 is an attractive and novel therapeutic approach for treating hypercholesterolemia	Mus musculus

Inhibitors

EC Number	Inhibitors	Comment	Organism	Structure
3.4.21.61	ISIS 394814	most potent antisense oligonucleotide. Administration to high fat-fed mice for 6 weeks reduces hepatic PCSK9 mRNA levels by 92%, total cholesterol and LDL by 53% and 38%, respectively. Inhibition of PCSK9 expression results in a 2fold increase in hepatic LDLR protein levels	Mus musculus

Organism

EC Number	Organism	UniProt	Comment	Textmining
3.4.21.61	Mus musculus	-	C57BL/6 mice	-
3.4.21.61	Mus musculus C57BL/6	-	C57BL/6 mice	-

Source Tissue

EC Number	Source Tissue	Comment	Organism	Textmining
3.4.21.61	liver	-	Mus musculus	-

Synonyms

EC Number	Synonyms	Comment	Organism
3.4.21.61	PCSK9	-	Mus musculus
3.4.21.61	proprotein convertase subtilisin/kexin type 9	-	Mus musculus

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)